linjc16/ctgov huggingface dataset:
Acupuncture Treatment in Adults Undergoing Diagnostic OGD : A Double-Blind Placebo Controlled Randomized Trial

Study Overview
=================
Brief Summary
-----------------
To find out how the application of acupuncture needles to the proposed acupuncture points: Heart 7 (HT 7) and Pericardium 6 (PC 6) for reducing anxiety during Esophago-gastro-duodenoscopy (EGD)

Detailed Description
-----------------
Acupuncture is being used as one part of Chinese medicine for more than 2,500 years in treating diseases. Recent functional magnetic resonance imaging demonstrated that acupuncture can suppress the pain area in the brain so as to reduce the pain that felt by human subjects. Western medicine proposed the acupuncture mechanisms as to provoke the release of endogenous substances from central nervous system so in reducing pain. Many studies had been done using acupuncture in reducing pain for post-operation period, however, most of them were not very systematic and even some of them are leak of control group. Furthermore, to our knowledge, the use of acupuncture for reducing anxiety during EGD has not been previously investigated.

Official Title
-----------------
Acupuncture Treatment in Adults Undergoing Diagnostic Upper Gastrintestinal Endoscopy: A Double-Blind Placebo Controlled Randomized Trial

Conditions
-----------------
Anxiety

Intervention / Treatment
-----------------
* Device: Acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-70 undergoing elective unsedatant diagnostic EGD belonging to American Society of Anesthesia (ASA) classes 1 to 2 Exclusion Criteria: History of gastrectomy, esophagectomy, Whipple's operation and other gastrointestinal operations ASA class 3 to 4 Pregnancy Allergy to acupuncture needles Request sedation Previous experiences of EGD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Acupuncture|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anxiety elicited during EGD |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall tolerance, overall satisfaction, patient's willingness to repeat procedure and recovery time |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acupuncture, Endoscopy
Diet Intervention in Food Sensitive Patients With IgA Nephropathy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess whether a tailored diet, eliminating antigens to which IgA nephropathy patients have demonstrated sensitivity, will have an effect on proteinuria, renal function and other immunological variables.

Official Title
-----------------
A Pilot Study of 6 Months Diet Intervention in Food Sensitive Patients With IgA Nephropathy

Conditions
-----------------
IGA Nephropathy

Intervention / Treatment
-----------------
* Dietary Supplement: Tailored diet
* Dietary Supplement: Low antigen content diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Above 18 years IgA nephropathy (IgAN), verified by biopsy Proteinuria > 1 g/24 h Having signed informed consent form Exclusion Criteria: Participation in another clinical trial Patients with celiac disease Introduction of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers (ARB) during the last three months prior to inclusion Patients treated with immunosuppressive or systemic corticosteroid drugs within the last twelve months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tailored diet<br>Tailored diet according to demonstrated food sensitivity | Dietary Supplement: Tailored diet<br>* Tailored diet according to demonstrated food sensitivity, 6 months<br>|
| Experimental: Low-antigen content (LAC) diet<br>Low-antigen content diet | Dietary Supplement: Low antigen content diet<br>* Low-antigen content diet for one month<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proteinuria |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal function | Glomerular filtration rate (GFR) | 6 months | 
| IgA/IgG immune complexes, incl. glycosylation |  | 6 months | 
| IgA/IgG to dietary antigens |  | 6 months | 
| Hematuria |  | 6 months |
The Development of Incisional Hernia in Relation to Specimen Extraction Site After Laparoscopic Colorectal Surgeries

Study Overview
=================
Brief Summary
-----------------
This is a retrospec/ve cohort study of colon cancer patients who underwent laparoscopic colorectal surgeries at Prince Sultan Military Medical City (PSMMC) in Riyadh, Saudi Arabia. The aim of this study is to determine the best site for specimen extrac/on with lowest risk of developing incisional hernia a0er laparoscopic colorectal surgeries.

Official Title
-----------------
The Development of Incisional Hernia in Relation to Specimen Extraction Site After Laparoscopic Colorectal Surgeries: A Retrospective Single Centered Cohort Study

Conditions
-----------------
Hernia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The study included all colorectal cancer patients over 2 years who were followed up or admitted to PSMMC under the service of colorectal surgery unit and who underwent laparoscopic low anterior resection, left colectomy or right colectomy with an age of 16 years or older. Exclusion Criteria: Duplicated data, subjects younger than 16, patients with previous abdominal surgery, and surgically complicated cases which were converted to open surgery were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type of incision | The rate of incisional hernia development in relation to the incision site | Over 2 years |
Artificial Intelligence for Early Diagnosis of Esophageal Squamous Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
Esophageal squamous cell carcinoma is one of the most common malignant tumor of upper digestive tract. However, the detection rate and diagnosis accuracy of early esophageal squamous cell cancer is low. The aim of this study is to develop a computer-assisted diagnosis tool combining with optical magnifying endoscopy for early detection and accurate diagnosis of it.

Official Title
-----------------
Application of Artificial Intelligence for Early Diagnosis of Esophageal Squamous Cell Carcinoma During Optical Enhancement Magnifying Endoscopy

Conditions
-----------------
Artificial Intelligence, Optical Enhancement Endoscopy, Magnifying Endoscopy

Intervention / Treatment
-----------------
* Other: AI presentation
* Other: no AI presentation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: high risk patients for esophageal cancer aged 18 years or older; Histologically verified early esophageal squamous cell cancer. Exclusion Criteria: patients whose images of esophagus not suitable for the training, validation and testing the computer-assist diagnosis tool.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AI visible group<br>the endoscopic novices analyzing the images can see the automatic diagnosis of AI during the process | Other: AI presentation<br>* AI presentation means the automatic diagnosis information of AI and AI presentation means it is visible in the group.<br>|
| AI invisible group<br>the endoscopic novice analyzing the images can not see the automatic diagnosis of AI during the process | Other: no AI presentation<br>* AI presentation means the automatic diagnosis information of AI and no AI presentation means it is invisible in the group.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the diagnosis efficiency of the AI model | the sensitivity, specificity and accuracy of the AI model | 12 months |
Intensive Dysarthria Sessions in Adults and Children With Down Syndrome

Study Overview
=================
Brief Summary
-----------------
This research study is designed to investigate the feasibility and treatment effects of a behavioral speech treatment in adults and children with Down Syndrome (DS) and dysarthria. The speech sessions will provide an intensive, articulation-based intervention focused on increasing effort during speech production via use of clear speech. A single subject multiple baselines across subjects design will be employed in a total of six subjects divided into two groups of three. Changes in dependent measures will be determined by visual inspection, effect size determination, and time series analysis. The study follows accepted procedures in rehabilitation treatment and research and there are minimal foreseeable risks associated with participation.

Official Title
-----------------
Intensive Dysarthria Sessions in Adults and Children With Down Syndrome

Conditions
-----------------
Dysarthria, Down Syndrome

Intervention / Treatment
-----------------
* Behavioral: Speech sessions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults and children with Downs Syndrome and dysarthria Ages 8 years and older Ability to verbally communicate; follow simple commands and/or imitate others; hear speech at a conversational level; and participate in assessment and speech sessions activities Exclusion Criteria: Additional serious medical problems which prevent meaningful participation in the study.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Behavioral speech treatment<br> | Behavioral: Speech sessions<br>* Subjects will be instructed to use clear speech and increased effort when speaking.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Speech intelligibility | Speech intelligibility in sentences scored by naive listeners. | 3-6 months |
PD-1/PD-L1 Pathway Study on Septic Patients

Study Overview
=================
Brief Summary
-----------------
The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.

Detailed Description
-----------------
First, we will detect PD-L1 expression on PBMC of septic patients and healthy controls. Second, blockade of PD-1/PD-L1 pathway in vitro and stimulate with some biomolecules and then analyze the PBMC function and apoptosis by flow cytometry. Then, compare with healthy controls and find the differences.

Official Title
-----------------
PD-1/PD-L1 Pathway in T Lymphocyte Apoptosis and Monocyte Dysfunction in Septic Patients

Conditions
-----------------
Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who develop sepsis Exclusion Criteria: patients with cirrhosis or renal dysfunction patients with dyscrasia patients with autoimmunity diseases patients with severe cardiac and pulmonary diseases patients with hematological diseases patients with diabetes mellitus patients with malignant tumors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sepsis
Alternative to Two-Stage Hepatectomy

Study Overview
=================
Brief Summary
-----------------
Two-stage hepatectomy with or without portal vein embolization allows to treat multiple bilobar metastases expanding surgical indications for these patients. However, it has some related drawbacks: two operations are needed, and some patients do not complete the treatment strategy for disease progression. Using experience gained from our ultrasound guided resection policy we explored the safety and effectiveness of one-stage surgical procedures in patients otherwise recommended for the two-stage approach.

Official Title
-----------------
One-Stage Ultrasound-Guided Hepatectomy for Multiple Bilobar Colorectal Metastases: a Feasible and Effective Alternative to Two-Stage Hepatectomy

Conditions
-----------------
Colorectal Cancer, Liver Metastases

Intervention / Treatment
-----------------
* Procedure: One-stage ultrasound guided hepatectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients presenting with resectable colorectal cancer liver metastases (CLM) 4 or more lesions Bilobar involvement of the liver Contact or close adjacency (less than 0.5 cm) of at least one CLM with major intrahepatic vascular structures (1st or 2nd order portal branches and/or hepatic vein at caval confluence). Exclusion Criteria: Patients with 3 or less resectable CLM Patients with 4 or more resectable CLM but nor bilobar Patients with 4 or more bilobar resectable CLM without any lesion presenting condition of point 4 of the inclusion criteria
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Prospective cohort of consecutive patients who undergo surgery for colorectal cancer liver metastases | Procedure: One-stage ultrasound guided hepatectomy<br>* Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome was the safety of the procedure. To this purpose we studied morbidity, mortality, amount of blood loss, rate of blood transfusions, and postoperative trend of liver function tests. |  | 30-day and 90-day postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary outcome measure was the reliability of the procedure from an oncological standpoint. For this purpose we studied the rate of true local recurrence (cut-edge) after a minimum follow-up of 6 months. |  | Minimum Follow-up of 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intraoperative ultrasonography, colorectal liver metastases, hepatectomy, portal vein embolization, Liver
Outcome of Radiation Therapy in Operated Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
Study tolerability and toxicity of radiotherapy with or without chemotherapy for operated gastric cancer. Evaluate the efficacy of adjuvant radiotherapy with or without chemotherapy as regarding local control and overall survival.

Official Title
-----------------
Outcome of Radiation Therapy In Operated Gastric Cancer

Conditions
-----------------
Gastric Adenocarcinoma

Intervention / Treatment
-----------------
* Radiation: Radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age of the patient; ≥18 and ≤75 years. Histologically proven gastric or gastroesophageal adenocarcinoma. Pt received adjuvant Radiotherapy with or without chemotherapy with any protocol. Exclusion Criteria: Patient >75 years&<18 years. Histologically types other than adenocarcinoma . Metastatic patients (M1). Pt didn't recive radiotherapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: Radiotherapy|Adjuvant Radiotherapy in operated gastric cancer|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of Radiotherapy in operated gastric cancer | Disease Free Survival | Baseline |
Comparison of the Effect of Ondansetron and Combined Ondansetron and Betahistine on Postoperative Nausea and Vomiting After Gynecological Laparoscopy

Study Overview
=================
Brief Summary
-----------------
Many patients undergoing gynecologic laparoscopic surgery experience postoperative nausea and vomiting (PONV) despite prophylaxis and treatment with HT3 receptor antagonists such as ondansetron. Involvement of multiple types of receptors and factors may be a reason for inadequate control of PONV with a single agent. Betahistine, a histamine antagonist at H1 receptor and antagonist at H3 receptor, is widely used as a treatment of dizziness. Dizziness is one of the cause of nausea and vomiting. This study is to compare the effects of ondansetron and combined ondansetron and betahistine in preventing PONV in high-risk patients receiving intravenous opioid-based patient-controlled analgesia (IV-PCA) after gynecological laparoscopic surgery.

Conditions
-----------------
Nausea and Vomiting

Intervention / Treatment
-----------------
* Drug: ondansetron
* Drug: ondansetron-betahistine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient scheduled for elective gynecological laparoscopic surgery American society of Anesthesiologists physical class I, Ⅱ, between the ages of 20 and 70 years Exclusion Criteria: hepatorenal disease BMI > 35 kg/m2 allergy to ondansetron or betahistine gastrointestinal disease vomiting within 24h administration of antiemetics or opioids within 24h QT prolongation (QTc > 440ms) Pheochromocytoma pregnant problem with communication

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ondansetron-betahistine<br>ondansetron-betahistine group | Drug: ondansetron-betahistine<br>* The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1. The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.<br>|
| Placebo Comparator: ondansetron<br>ondansetron group | Drug: ondansetron<br>* The ondansetron group is given placebo (pyridoxin) instead of betahistine. The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative nausea and vomiting | evaluation of nausea and vomiting with verbal rating scale (VRS, 0, no nausea; 10, worst imaginable nausea) | at postoperative 24h |